Physician profile
Deval P Gadhvi
NPI 1518119700
$5,727.34
in general payments reported to CMS, 2019-2025
18 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.01 · 2020: $175 · 2021: $1,929 · 2022: $1,055 · 2023: $1,092 · 2024: $919 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,534.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,691.78 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $1,214.61 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,175.97 | 2020-2024 | Breztri, Farxiga |
| Medtronic, INC. | $306.08 | 2023-2024 | Corevalve Evolut R, Signia |
| Abbvie INC. | $299.68 | 2021-2025 | |
| Pfizer INC. | $205.56 | 2023-2025 | |
| Gilead Sciences, INC. | $189.95 | 2019-2025 | Yeztugo |
| Amgen INC. | $168.75 | 2021-2025 | Repatha |
| Viiv Healthcare Company | $157.61 | 2022-2025 | Apretude |
| Novo Nordisk INC | $84.56 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.04 | 2024-2025 | Xifaxan, Trulance |
| Intra-Sana Laboratories | $45.55 | 2024-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Biohaven Pharmaceutical Holding Company LTD. | $32.10 | 2022 | |
| Lilly USA, LLC | $21.73 | 2025 | Mounjaro, Zepbound |
| Linus Health, INC. | $20.23 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.44 | 2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.89 | 2021 | |
| Allergan, INC. | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deval Gadhvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.